DrugBiological
Cetrelimab clinical trials
Also written JNJ-63723283.
- studies test it
- 11
- open now
- 1
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the cetrelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Janssen Research & Development, LLC (8) · M.D. Anderson Cancer Center (1) · University Medical Center Groningen (1) · Rahul Aggarwal (1)
Often tested with
Tested in the same studies.
Gemcitabine-Releasing Intravesical System (3) · Apalutamide (2) · Amivantamab (1) · Cabazitaxel (1) · Carboplatin (1) · Niraparib (1) · Daratumumab (1) · Nivolumab (1)
Studies
Open first, then newest update. How each study uses cetrelimab is read from its arms, and is right about nine times in ten.
Testing it · 11
- CD8 PET Imaging in Metastatic Solid TumoursRecruitingPhase 2University Medical Center GroningenNCT06534190Written as Cetrelimab
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04658862Written as Cetrelimab
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive, not recruitingPhase 2Janssen Research & Development, LLCNCT04640623Written as Cetrelimab
- A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT05908734Written as Cetrelimab
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT05714202Written as Cetrelimab
- Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04592237Written as Cetrelimab
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced CancersActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT02908906Written as JNJ-63723283
- Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerTerminatedPhase 2Rahul AggarwalNCT04926181Written as Cetrelimab
- A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedPhase 2/3Janssen Research & Development, LLCNCT03357952Written as JNJ-63723283
- A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 1Janssen Research & Development, LLCNCT05242445Written as Cetrelimab
- A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerCompletedPhase 1Janssen Research & Development, LLCNCT03551782Written as Cetrelimab 480 mg
Given in every arm · 9 — cetrelimab is usual care beside what is tested
- A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid TumorsRecruitingPhase 1Johnson & Johnson Enterprise Innovation Inc.NCT06311578Written as Cetrelimab
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Cetrelimab
- A Study of JNJ-1761981 in Participants With Solid TumorsRecruitingPhase 1Johnson & Johnson Enterprise Innovation Inc.NCT07525141Written as Cetrelimab
- A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerRecruitingPhase 1Ankyra Therapeutics, IncNCT07027514Written as Cetrelimab
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2Janssen Research & Development, LLCNCT03431350Written as Cetrelimab 240 mg
- A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingPhase 1Johnson & Johnson Enterprise Innovation Inc.NCT06116786Written as Cetrelimab
- A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT03473743Written as Cetrelimab
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderCompletedPhase 2Janssen Research & Development, LLCNCT04919512Written as Cetrelimab
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersCompletedPhase 1Janssen Pharmaceutical K.K.NCT03547037Written as JNJ-63723283
Codes
What other systems call cetrelimab · ClinicalTrials.gg INT017223
- UNII (FDA) LYK98WP91FCETRELIMABOne source FDA
- NCI Thesaurus C129448CetrelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LYK98WP91F | CETRELIMAB | One source FDA |
| NCI Thesaurus | C129448 | Cetrelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.